![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 26, 23587-23595, June 28, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
**
From the
Unidad de Investigación
"Carlos Méndez" del Centro Universitario de Investigaciones
Biomédicas de la Universidad de Colima, 23000 Colima,
México, § Molecular Systems, Merck Research
Laboratories, West Point, Pennsylvania 19486 and the Departments of
¶ Medicine and
Physiology, and ** Eccles Program
in Human Molecular Biology and Genetics, University of Utah,
Salt Lake City, Utah 84112
Received for publication, January 15, 2002, and in revised form, March 21, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The structural determinants for the
voltage-dependent block of ion channels are poorly
understood. Here we investigate the voltage-dependent block
of wild-type and mutant human ether-a-go-go related gene (HERG)
K+ channels by the antimalarial compound chloroquine.
The block of wild-type HERG channels expressed in Xenopus
oocytes was enhanced as the membrane potential was progressively
depolarized. The IC50 was 8.4 ± 0.9 µM
when assessed during 4-s voltage clamp pulses to 0 mV. Chloroquine also
slowed the apparent rate of HERG deactivation, reflecting the inability
of drug-bound channels to close. Mutation to alanine of aromatic
residues (Tyr-652 or Phe-656) located in the S6 domain of HERG
greatly reduced the potency of channel block by chloroquine
(IC50 > 1 mM at 0 mV). However, mutation of
Tyr-652 also altered the voltage dependence of the block. In contrast to wild-type HERG, block of Y652A HERG channels was diminished by
progressive membrane depolarization, and complete relief from block was
observed at +40 mV. HERG channel block was voltage-independent when the
hydroxyl group of Tyr-652 was removed by mutating the residue to Phe.
Together these findings indicate a critical role for Tyr-652 in
voltage-dependent block of HERG channels. Molecular modeling was used to define energy-minimized dockings of chloroquine to
the central cavity of HERG. Our experimental findings and modeling suggest that chloroquine preferentially blocks open HERG channels by
cation- HERG1
(1) encodes the pore-forming subunits of channels that conduct the
rapid delayed rectifier K+ current, IKr (2, 3).
Mutation of HERG is a common cause of inherited long QT
syndrome, a disorder of cardiac repolarization that predisposes
affected individuals to torsade de pointes arrhythmia and sudden death
(4). Acquired long QT syndrome is far more common than inherited long
QT syndrome and is most often caused by block of HERG channels as a
side effect of treatment with commonly used medications including
antiarrhythmic, antihistamine, antibiotic, and psychoactive agents (5,
6). Although rare, treatment with the antimalarial drug chloroquine has
also been associated with acquired arrhythmias. Prolonged therapy with
chloroquine can lead to electrocardiographic changes including T-wave
depression or inversion and prolonged QRS and QT intervals (7, 8). Prolonged QT intervals caused by chloroquine can induce torsade de
pointes (9, 10). At the cellular level, chloroquine decreases the
maximum upstroke velocity due to block of sodium current and prolongs
the duration of action potentials due to block of inward rectifier
current (IK1) and IKr (11). Elucidating the
molecular mechanisms of HERG channel block by chloroquine and other
drugs may enable the rational design of new pharmaceuticals devoid of this unwanted side effect.
The structural basis of HERG channel block by several potent drugs was
recently investigated using alanine-scanning mutagenesis (12). Mutation
of several amino acid residues of the HERG channel reduced the block of
HERG current by several chemically unrelated compounds. These key
residues were located on the S6 domain or near the pore helix, and
homology modeling predicted that they faced the central cavity of the
channel. Binding to two residues in particular (Tyr-652 and Phe-656)
was proposed to be the most important determinants of the binding site.
A critical role for Phe-656 had been proposed previously (13) for
binding of the antiarrhythmic agent dofetilide and quinidine. Most HERG
channel blockers that have been studied in detail (e.g.
MK-499, dofetilide, and cisapride) are high affinity ligands and
exhibit little or no voltage-dependent block. In contrast,
blockade of HERG channels by low affinity ligands (e.g.
chloroquine, quinidine) is characterized by significant
voltage-dependent kinetics and steady state effects (11).
Two models have been proposed to explain voltage-dependent
block of ion channels by drugs (14). The modulated receptor model proposes that the binding affinity (Kd) of a drug
varies as a function of channel state. For example, many local
anesthetic agents appear to preferentially block sodium channels in the
open and/or inactivated state but have little affinity for the closed states that predominate at the resting membrane potential. However, the
molecular basis for the apparent state-dependent change in binding affinity is poorly understood. An alternative hypothesis is the
guarded receptor model that assumes a constant and state-independent Kd but proposes that access to the binding site by
charged drugs is prevented ("guarded") by the activation gate
(15-17).
Here we characterize the block by chloroquine of WT and mutant HERG
channels expressed in Xenopus oocytes. Our results suggest a
molecular explanation for voltage-dependent block of HERG
channels by chloroquine that further implicates the importance of the
aromatic residues located on the S6 domains. We propose that block of
HERG by chloroquine requires channel opening and sequential interaction with two aromatic residues (Phe-656 and Tyr-652) that face the central
cavity of the HERG channel. This model incorporates features of both
the guarded receptor and the modulated receptor hypotheses to describe
the voltage-dependent block of HERG channels by chloroquine.
Molecular Biology--
Several HERG channel mutants (V625A,
Y652A, and F656A) were chosen for study based on our previous finding
(12) that these mutations decreased the potency of channel block by
MK-499. These and additional (Y652F, Y652T, and Y652E) missense
mutations were introduced into WT HERG cDNA by the megaprimer
method (18) as described previously (12) and subcloned into the pSP64
plasmid expression vector (Promega, Madison, WI). Before use in
experiments, each construct was confirmed with restriction mapping and
DNA sequencing of the PCR-amplified segment. G628C/S631C HERG was kindly provided by G.-Y. Tseng. Complementary RNAs for injection into
oocytes were prepared with SP6 Cap-Scribe (Roche Molecular Biochemicals) following linearization of the expression construct with
EcoRI.
Voltage Clamp of Oocytes--
Isolation and maintenance of
Xenopus oocytes and cRNA injections were performed as
described (19). A GeneClamp 500 amplifier (Axon Instruments,
Burlingame, CA) and standard two microelectrode voltage clamp
techniques (20) were used to record currents. Currents were recorded at
room temperature (22-24 °C) 2-4 days after cRNA injection. Glass
microelectrodes were filled with 3 M KCl, and their tips
were broken to obtain resistances of 0.5 to 1 megohms. The external
solution contained 96 mM NaMes, 2 mM KMes, 2 mM CaMes2, 5 mM HEPES, 1 mM MgCl2, adjusted to pH 7.6 with
methanesulfonic acid. Voltage commands were generated using pCLAMP
software (version 6; Axon Instruments, Burlingame, CA). Currents were
not corrected for leak or endogenous currents, and capacitance
transients were not nulled. To generate current-voltage (I-V)
relationships, pulses were applied in 10-mV increments at a frequency
of 0.05 Hz. Test potentials ranged from
The time-dependent block of current was determined by
dividing current recorded during a 4-s pulse in the presence of drug (Idrug) by the current recorded before application of drug
(Icontrol). The resulting ratio,
Idrug/Icontrol, was fit with a single
exponential function to obtain the time constant for the onset of HERG
current blockade. Currents measured at the end of 4-s test pulses were used to measure steady state fractional block ("fraction blocked"), defined as the amplitude of current reduced by drug divided by control
current amplitude.
Chloroquine (Sigma) was dissolved in the external solution to obtain
the desired drug concentrations. Oocytes were exposed to chloroquine
solutions until steady state effects were achieved, usually in about 15 min. To determine the concentration-effect relationships, a single
oocyte was exposed to cumulative concentrations of chloroquine.
Data Analyses--
Data are presented as mean ± S.E.
Clampfit software (Axon Instruments) was used to perform nonlinear
least squares kinetic analyses of time-dependent currents.
The fractional block of current (y) was plotted as a
function of drug concentration ([D]), and the data were
fit with Hill Equation 1 to determine the concentration (IC50) required for 50% block of current magnitude and the
Hill coefficient, h.
Molecular Modeling--
The 1BL8 KcsA structure (21) was
retrieved from the Protein Data Bank and used as the template for an
HERG homology model. Based on a BLAST search of protein crystal
structures, the HERG channel turret (amino acids 572-609) was modeled
after 3PRC (residues Met-10 to Met-45). The S5 domain was modeled using
an alignment between the outer helix of KcsA and the putative S5 of
HERG. The MOE program (Chemical Computing Group) was used to produce a
homology model for the HERG monomer. Energy minimization was performed to eliminate close contacts but not to allow helix unfolding. The
tetramer was constructed by copying the derived monomer conformation onto the KcsA tetramer. Low energy conformations of chloroquine were
generated and docked using the Flexible Ligands Oriented on Grid
procedure (22).
Block of WT HERG Current by Chloroquine--
Currents were
elicited by 4-s depolarizing pulses to potentials ranging from
The time- and voltage-dependent block of WT HERG current by
chloroquine was studied in greater detail using a concentration of 15 µM. Superimposed traces of currents recorded during a 4-s pulse to
The ratio Idrug/Icontrol as a function of time
during the pulse was used to estimate initial block and the onset rate
of block (Fig. 2, C and D). The current ratio had
an initial value of 1.0, indicating that channels completely recovered
from block during the 16-s interval between test depolarizations. The
time constants ( Removal of Inactivation Reduces Sensitivity but Not Voltage
Dependence of HERG Block--
The hypothesis that chloroquine might
preferentially bind to inactivated channels was tested with G628C/S631C
HERG, a mutant channel that does not inactivate (24). G628C/S631C
current was reduced by chloroquine in a
concentration-dependent manner (Fig. 3, A and B).
Similar to WT HERG, the block of current conducted by mutant channels
was increased as a positive function of voltage (Fig. 3C).
The IC50 for current block at +20 mV was 27.2 ± 2.7 µM (Fig. 3D), 4-fold less sensitive than WT
channels (p < 0.05). These findings indicate that
although removal of inactivation reduced the steady state block of
HERG, it did not affect the voltage dependence of block.
Characterization of the Chloroquine-binding Site--
Several
residues located on the S6 and pore helix domains of HERG compose the
putative binding site for methanesulfonanilide drugs such as MK-499
(IC50 = 34 nM). Mutation of Val-625 of the pore
helix or Tyr-652 or Phe-656 of the S6 domain to Ala caused the most
profound reductions in potency for block of HERG current by MK-499
(12). Chloroquine is a weak blocker of HERG, so it was possible that
the putative binding sites for this drug would differ from those
determined previously for the high affinity ligand MK-499 (12).
Therefore, we determined the concentration-effect relationship for
chloroquine on V625A, Y652A, and F656A HERG channels and compared the
potency for block to WT channel current. For this measurement, current
was measured at the end of a 4-s pulse to 0 mV for WT, V625A, and Y652A
HERG channels. The reduction of current caused by exposure to 50 µM chloroquine was nearly identical for WT and V625A HERG
channels (Fig. 4, A and
B). Because the V625A mutation reduces K+
selectivity of the HERG channel, the tail currents were inward at
Similar to our previous findings with MK-499, mutation of aromatic
residues located in the S6 domain greatly reduced chloroquine potency.
The IC50 for block of Y652A HERG was increased ~500-fold relative to WT HERG (Fig. 4C). To increase the amplitude of
poorly expressing F656A mutant channels, tail currents were recorded at
Time- and Voltage-dependent Block of Tyr-652 Mutant
HERG Channels--
The block of Y652A HERG channels was more prominent
for weak than for strong membrane depolarization, a pattern opposite to that observed for WT current. Voltage-dependent block is
obvious in the superimposed current traces of Fig.
5, A and B, where
150 µM drug reduced steady state current by about 35% at
a test potential of
The ratio Idrug/Icontrol during 4-s test pulses
to
Chloroquine had qualitatively similar effects on Y652T and Y652E HERG
channels (Fig. 6). The IC50
measured at 0 mV was increased 500-fold for both mutant channels
compared with WT channels. Fractional block by 150 µM
chloroquine varied as a function of test potential, diminishing from
0.68 ± 0.04 at
We next determined the effect of a more conserved amino acid
substitution of Tyr-652. Phenylalanine only differs from tyrosine by
the absence of an Chloroquine Interacts with Phe-656 and Tyr-652 of the S6 Domain to
Cause Open Channel Block of HERG--
Block of HERG K+
channels by chloroquine exhibits several features typical of an open
channel blocker. First, there was no block of initial current in
response to a depolarizing pulse, consistent with a lack of interaction
with channels in the closed state. Second, the extent and rate of onset
of block was voltage-dependent, increasing at more
depolarized potentials. Third, slowed deactivation and tail current
crossover in the presence of chloroquine suggested that when drug was
bound to the channel it prevented closure of the activation gate. This
is similar to the so-called foot in the door mechanism first
hypothesized by Armstrong (23) to describe the kinetics of unblock of
squid axon K+ channels by tetraethylammonium
derivatives (25). The inactivation-deficient mutant channel,
G628C/S631C HERG, was about 4 times less sensitive to block by
chloroquine. It is likely that the charged form of chloroquine is
responsible for channel block because the alkylammoniums (N2 and N3 in Fig.
8C, inset) have
pKa values of 8.4 and 10.8, respectively. The drug
would be >99% charged at normal intracellular pH. Thus, the
positively charged form of chloroquine preferentially blocks open HERG
channels by a foot in the door mechanism, and block is enhanced by, but
not dependent on, inactivation.
Chloroquine blocked HERG current with a potency similar to that of
quinidine (13, 26, 27), mefloquine (28), sparfloxacin (29), and
vesnarinone (30, 31). All these compounds exhibit increased block with
increasing membrane depolarization, and channels fully recover from
block in less than a minute at a holding potential of
Tyr-652 is located one helical turn above Phe-656 in the S6 domain and
also faces the central cavity of the channel pore. We found that
mutation of Tyr-652 to Ala, Thr, or Glu increased the IC50
for block by chloroquine of HERG by >500-fold. In a previous study
(12) we also found that mutation of Val-625 to Ala, located at the base
of the pore helix and adjacent to the K+ selectivity
filter, reduced the potency of MK-499 but not cisapride or terfenadine.
Chloroquine is more like these latter two drugs with respect to lack of
interaction with Val-625. Thus, our findings with chloroquine provide
further evidence that HERG channel blockers, despite significant
structural diversity, interact principally with one or more aromatic
residues of the S6 domain.
Substitution of Tyr-652 with Ala or Phe only slightly altered the
gating properties of HERG channels but markedly influenced voltage-dependent block. Block of WT HERG current by
chloroquine was enhanced by progressive depolarization. In contrast,
block of Y652A HERG current was diminished by increased depolarization, whereas block of Y652F current was relatively insensitive to voltage. Thus, substitution of a phenyl with a benzyl moiety (Y652F) eliminated the voltage dependence of HERG block, whereas removal of the aromatic group reversed the voltage dependence of block. Considering the evident
importance of the A Model to Explain Voltage-dependent Block of WT and
Mutant HERG Channels by Chloroquine--
Molecular modeling was used
to define two energy-minimized dockings for chloroquine inside the
central cavity of a homology model of the HERG channel (Fig. 8). It is
important to note that 1) other ligand dockings are plausible, 2) the
homology model is based on a static KcsA crystal structure, and 3) that
the most important S6 residues comprising the putative binding sites
(Tyr-652 and Phe-656) likely change orientation in response to channel gating. Despite these obvious limitations, the dockings illustrated in
Fig. 8 provide a framework for the discussion of a model that we base
primarily on experimental findings.
As shown in Fig. 2F, chloroquine blocks with relatively low
potency to WT HERG channels in response to a weak depolarization from a
holding potential of
Blockade of Y652F HERG channels was relatively insensitive to
transmembrane voltage. Perhaps mutation of Tyr-652 to Phe reduced the
affinity of the depolarization-favored drug-binding site to a value
similar to the affinity defined by interaction with multiple Phe-656
residues. In the absence of the Tyr
Chloroquine slowed the apparent rate of WT HERG current deactivation
but increased the rate of Tyr-652 mutant HERG current deactivation.
Slowed deactivation and crossover of the tail currents of WT HERG
channels are consistent with a foot in the door mechanism, where it is
assumed that channels cannot close until the drug unbinds from the
channel. The increase in the apparent rate of deactivation of Tyr-652
mutant HERG channels in the presence of drug is consistent with
re-binding of drug to Phe-656 residues located lower in the cavity that
would be favored upon membrane repolarization. In the case of Y652A
channels, re-block presumably occurs by a drug molecule that is present
in the central cavity but not bound to the S6 domain.
Non-aromatic Substitutions of Tyr-652 Residues--
The block of
Y652A HERG channels by chloroquine was completely reversed by strong
depolarization. This was a surprising result because an increase in
membrane depolarization should favor movement of a positively charged
drug further into the central cavity and either result in no change in
block or perhaps an increased block as was observed for WT channels.
Moreover, a single hydrated K+ ion located in the middle of
the central cavity and coordinated by the pore helices is evidently
vital for ion conduction in KcsA and presumably voltage-gated
K+ channels (21, 38), and binding of the N-terminal
inactivation peptide to S6 residues that line the channel pore induces
inactivation (39). It may seem unexpected that Y652A HERG channels
would conduct K+ ions normally if chloroquine was present
within the central cavity. However, there is a precedent for such an
effect in the L-type Ca2+ channel. Dihydropyridine
antagonists block current conducted by
There are at least two alternative explanations for the reverse voltage
dependence of Y652A HERG channel block. For example, chloroquine might
bind to a low affinity site located on the extracellular side of the
channel pore and be increasingly knocked off by outward flux of
K+ as the membrane potential was progressively depolarized.
Alternatively, a strong depolarization could cause rotation of S6 and a
reduction in binding affinity, allowing drug to diffuse back into the
cytoplasm. This seems unlikely because the positive transmembrane
potential would not favor the diffusion of a positively charged drug
into the cytoplasm. Moreover, neither of these alternative mechanisms is compatible with the finding that block of Y652F by chloroquine was
voltage-independent.
In summary, we propose that depolarization-dependent HERG
channel block by chloroquine is a multistep process that involves sequential binding of a drug molecule to low and high affinity sites
that are accessible only when the channel is in the open state.
Repolarization of the membrane promotes recovery from block, but
channels can only close after drug has unbound from Tyr-652. This model
incorporates features of both the guarded receptor hypothesis
(requirement for channel opening) and the modulated receptor hypotheses
(binding affinity that varies with voltage) to describe the
voltage-dependent block of HERG channels by chloroquine.
and
-stacking interactions with Tyr-652 and Phe-656 of
multiple subunits.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 to +40 mV and were applied
from a holding potential of
80 mV. Deactivating (tail) currents were
measured at
70 mV.
Statistical comparisons between experimental groups were
performed using analysis of variance and Dunnett's method.
Differences were considered significant at p < 0.05.
(Eq. 1)
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 to
+40 mV. The step currents measured at the end of 4-s pulses and the
tail currents measured on return to
70 mV were reduced in a
concentration-dependent manner by chloroquine (Fig.
1, A and B). The
I-V relationship for step currents peaked at
20 mV in control and at
30 mV in the presence of chloroquine. Block of step currents was
pronounced at more depolarized test potentials (Fig. 1C),
indicating voltage-dependent block. The decrease in tail
currents by chloroquine was also voltage-dependent (Fig.
1D), with greater block apparent at more depolarized
potentials. For example, 5 µM chloroquine reduced peak
tail currents on average by 1% at
50 mV and 36% at +40 mV.

View larger version (19K):
[in a new window]
Fig. 1.
Effect of chloroquine on HERG current in
Xenopus laevis oocytes. A and
B, representative HERG currents recorded from an oocyte
before (A) and after (B) incubation with 15 µM chloroquine. Currents were recorded at test potentials
between
70 and +40 mV. Tail currents were recorded after
repolarization to
70 mV. C, I-V relationships for currents
measured at the end of the 4-s test pulse before and after application
of 5, 15, and 30 µM chloroquine (n = 5).
Currents were normalized to control current at
20 mV for each oocyte.
D, I-V relationships for peak tail currents before and after
application of 5, 15, and 30 µM chloroquine. Currents
were normalized to the peak current measured in control conditions for
each oocyte.
50 mV or +10 mV, before and after addition of 15 µM chloroquine, are shown in Fig.
2, A and B.
Time-dependent block of current during the pulse made the
rate of current activation appear faster, whereas delayed recovery from
block initiated by repolarization slowed the rate of deactivation (Fig.
2, A and B). The slower apparent rate of
deactivation has been described for other compounds as a "foot in the
door" effect, meaning that drug must first exit the central cavity of
the channel before the activation gates ("door") can close
(23).

View larger version (22K):
[in a new window]
Fig. 2.
Voltage-dependent block of WT
HERG channel current by chloroquine. A and
B, superimposed traces of currents elicited during 4-s test
pulses to
50 mV (A) or +10 mV (B) before and
after exposure to 15 µM chloroquine. Tail currents were
measured upon repolarization to
70 mV. Note that tail currents in the
presence of drug are initially smaller than control currents but cross
over during the pulse to
70 mV to become larger than control
currents. C and D, plot of the ratio
Idrug/Icontrol during 4-s pulses shown in
A and B. Note that at time = 0 there is no
block of current (Idrug/Icontrol = 1). The time
constant describing the rate of onset of HERG channel block was
determined by a single exponential fit of the current ratio.
E, time constants for onset of block of current by
chloroquine plotted as a function of test potential
(Vt). F, fractional block of WT HERG
currents, measured at the end of 4-s pulses and plotted as a function
of test potential.
) for the onset rate of block were
voltage-dependent (17 ± 3 mV for
e-fold change in
, where e = 2.71828),
decreasing with membrane depolarization from 420 ms at
50 mV to 140 ms at +40 mV (Fig. 2E). Because the onset of block was
relatively fast, steady state reduction of current by 15 µM chloroquine was adequately estimated using a 4-s
pulse. Steady state fractional block of current varied as a function of
test potential, decreasing from 0.18 at
50 mV to >0.7 at potentials
positive to 0 mV (Fig. 2F). These findings demonstrate that
15 µM chloroquine blocks open, but not closed, WT HERG
channels and that steady state block was increased as a positive
function of membrane potential.

View larger version (26K):
[in a new window]
Fig. 3.
Chloroquine blocks inactivation-removed HERG
channels. A and B, G628C/S631C HERG currents
recorded before and after exposure of oocyte to 50 µM
chloroquine. C, normalized I-V relationships for G628C/S631C
HERG currents (n = 5). D,
concentration-dependent block by chloroquine of G628C/S631C
HERG current recorded at a test pulse of +20 mV. The IC50
was 27.2 ± 2.7 µM; h = 0.84 (n = 5)
70
mV. Unlike MK-499, where the V625A mutation reduced potency by 54-fold
(12), this mutation did not alter the potency of channel block by
chloroquine. The IC50 values were 8.4 ± 0.9 µM for WT and 7.2 ± 0.8 µM for V625A
HERG (Fig. 4C).

View larger version (23K):
[in a new window]
Fig. 4.
Concentration-dependent block of
WT and mutant HERG channels by chloroquine. A and
B, superimposed traces of WT HERG (A) and V625A
(B) currents elicited by application of depolarizing pulses
to +0 mV, before and after exposure to 15 µM chloroquine.
C, concentration-effect relationship for block of HERG
current by chloroquine. The IC50 was 8.4 ± 0.9 µM (h = 0.81) for WT, 7.2 ± 0.8 µM (h = 0.76) for V625A (n = 5), and
>3 mM for Y652A (n = 6). D and
E, superimposed traces of WT HERG (D) and Phe-656
HERG (E) currents elicited by application of depolarizing
pulses to 0 mV and upon repolarization to
140 mV, before and after
exposure of chloroquine at 50 µM (D) and 500 µM (E). F, concentration-effect
relationship for current inhibition by chloroquine. The
IC50 determined by using a Hill equation was 19.7 ± 1.7 µM (h = 0.9) for WT HERG, and >10
mM for Phe-656 HERG (p < 0.01).
n = 4-6 oocytes for each channel type.
140 mV instead of
70 mV (Fig. 4, D and E). By
using this protocol, the IC50 for WT current was increased
to 19.7 ± 1.7 µM. Block of F656A HERG was minimal
at 0.5 mM, indicating a decrease in potency of nearly 3 orders of magnitude compared with WT HERG (Fig. 4F;
p < 0.01). These findings suggest that chloroquine
blocks WT channels by interaction with Tyr-652 and Phe-656 residues
located in the S6 domain, but it does not interact with Val-625 located at the base of the pore helix.
30 mV but reduced current by only 5% at +20 mV.
Furthermore, the apparent rate of Y652A HERG tail current deactivation
was much faster in the presence of drug (Fig. 5, A and
B), as opposed to the slowed deactivation associated with
block of WT current (Fig. 2).

View larger version (20K):
[in a new window]
Fig. 5.
Voltage-dependent block of Y652A
HERG currents by chloroquine. A and B,
superimposed traces of currents elicited during depolarizing pulses to
30 mV (A) or +20 mV (B) and return to
70 mV,
before and after exposure to 150 µM chloroquine.
C and D, onset of HERG channel block by 150 µM chloroquine assessed during depolarizing voltage steps
to
30 and +20 mV, respectively. E, time constants for
onset of block and unblock of Y652A HERG current by chloroquine plotted
as a function of test potential (Vt). Dashed
curve represents block onset data for WT HERG. F,
fractional block of Y652A HERG currents plotted as a function of test
potential. Dashed curve shows fraction blocked for WT HERG.
G, tail currents (normalized to peak of control current)
measured before and after exposure of an oocyte to 50, 150, and 500 µM chloroquine. H, Fast (
f) and
slow (
s) time constants of HERG deactivation at
70
mV.
30 or +20 mV is plotted in Fig. 5, C and D.
The current ratio had an initial value of 1, indicating that block
occurred only after channels had opened. The time course of the current
ratio was biphasic, with an initial rapid phase of block followed by a
slower partial recovery from block. The time constants for the onset
and recovery from block were strongly voltage-dependent and
decreased at more depolarized potentials (Fig. 5E). The
voltage dependence for block onset (16 ± 3 mV/e-fold change in
) was almost the same as
measured for WT HERG. Steady state block of Y652A HERG, expressed as
fractional block, was also voltage-dependent and varied
from 0.7 at
50 mV to 0 at +40 mV (Fig. 5F). These findings
demonstrate that chloroquine blocked Y652A channels only after opening
of the activation gate and that block decreases with increasing
membrane depolarization. The increased rate of deactivation (Fig. 5,
A and B) was likely caused by rapid re-block of
mutant channels by drug in response to repolarization to
70 mV. In
support of this interpretation, the rate of Y652A HERG deactivation was
strongly dependent on chloroquine concentration (Fig. 5, G
and H).
30 mV to 0.01 ± 0.01 at +40 mV for Y652T
HERG (n = 4), and from 0.72 ± 0.03 at
30 mV to
0.17 ± 0.03 to +40 mV for Y652E HERG (n = 5).
Unblock of current observed with increasing depolarization suggests
that the drug dissociates from a receptor site and either enters the
cytosol or moves into a position within the central cavity that does
not block K+ conduction. The results presented below
suggest the second explanation is more likely.

View larger version (22K):
[in a new window]
Fig. 6.
Voltage-dependent block of Y652T
and Y652E HERG currents by chloroquine. A and
B, superimposed traces of Y652T HERG currents elicited
during depolarizing pulses to
30 mV (A) or +20 mV
(B) and return to
70 mV, before and after exposure to 500 µM chloroquine. C and D,
onset of Y652T HERG channel block by 500 µM chloroquine
assessed during depolarizing voltage steps to
30 and +20 mV,
respectively. E, time constants for onset of block and
unblock of Y652T and Y652E HERG currents by chloroquine plotted as a
function of test potential (Vt). F,
fractional block of Y652T and Y652E HERG currents plotted as a function
of test potential. Dashed curves depict data for WT
HERG.
OH. We had shown previously (12 that mutation of
Tyr-652 to Phe had no significant effect on channel block by MK-499. In
contrast to MK-499, the Y652F mutation reduced the potency of
chloroquine by more than 10-fold. More surprising, however, was the
finding that block of Y652F HERG current was nearly
voltage-independent. Block was nearly the same when currents were
elicited with a pulse to
50 or +10 mV, and the apparent rate of
deactivation was only slightly faster in the presence of drug (Fig.
7, A and B).
Similar to WT and Y652A HERG channels, block of Y652F channels only
occurred after the channels were opened (as indicated by the initial
Idrug/Icontrol ratio of 1, Fig. 7, C
and D), and the rate of block onset was faster at more depolarized potentials (16 ± 3 mV/e-fold change
in
; Fig. 7E). Steady state fractional block of Y652F
channels was voltage-independent at potentials below 0 mV and only
weakly voltage-dependent at potentials above +10 mV (Fig.
7F). These findings suggest an essential role for the
OH
group of Tyr-652 in the voltage-dependent block of WT HERG
by chloroquine.

View larger version (22K):
[in a new window]
Fig. 7.
Voltage-dependent block of Y652F
HERG currents by chloroquine. A and B,
superimposed traces of currents elicited during application of
depolarizing pulses to
50 mV (A) or +10 mV (B)
and upon repolarization to
70 mV, before and after exposure to 150 µM chloroquine. C and D, onset of
HERG channel block by 150 µM chloroquine assessed during
depolarizing voltage steps to
50 and +10 mV, respectively.
E, time constants for onset of block of Y652F HERG current
by chloroquine plotted as a function of test potential
(Vt). F, fractional block of Y652F HERG
currents plotted as a function of preceding test potential.
Dashed curves depict data for WT HERG.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (98K):
[in a new window]
Fig. 8.
Docking of chloroquine to S6 domains
of the HERG K+ channel. A, HERG homology
model of S5-S6 domains, showing three subunits and the region portrayed
in an expanded view in B. B, stereoview of
docking 1 of chloroquine to the HERG channel. In this docking, the
quinoline
-stacks with Phe-656 on three subunits (two are labeled),
N3 H-bonds with Ser-649 (pink), and the attached
diethyl groups are in hydrophobic contact with Tyr-652
(orange, labeled) of an adjacent subunit. C, HERG
homology model of S5-S6 domains, showing two subunits and the region
portrayed in an expanded view in D. Lower panel shows
structure of chloroquine with the three N atoms labeled. D,
stereoview of docking 2 of chloroquine to the HERG channel. In this
docking, the quinoline
-stacks with Tyr-652 and Phe-656
(red, both labeled) of a single subunit, and N2
H-bonds with Ser-649 (yellow) and an ethyl group attached to
N3 is in hydrophobic contact with Tyr-652
(yellow, labeled) of the adjacent subunit.
80 mV. In
contrast, methanesulfonanilide drugs such as MK-499 and dofetilide are
high affinity ligands with IC50 values in the 10-100
nM range and do not exhibit such obvious
voltage-dependent block of current (32, 33). Moreover, the
recovery from block of HERG channels by methanesulfonanilides is
extremely slow and incomplete (33, 34). Despite these kinetic
differences, the amino acids that compose the binding site for low and
high affinity blockers appear to be similar. The most important residue
appears to be Phe-656 that is located in the S6 domain and faces the
central cavity of the HERG channel pore. Mutation of Phe-656 to Val
reduced the IC50 for block of HERG by 120-fold for
dofetilide and 27-fold for quinidine (13). Mutation of Phe-656 to Ala
caused a similar shift in the IC50 for cisapride (30-fold)
and terfenadine (100-fold) but a much greater shift in the
IC50 for MK-499 (650-fold) (12) and chloroquine
(>500-fold, this study). Together these findings suggest that binding
to Phe-656 is a crucial and perhaps first step in block of HERG by both
low and high affinity ligands. This could occur by interaction of a
positively charged amine (N2 or N3) of
chloroquine with the negative electrostatic potential provided by the
face of a Phe-656 residue. Such cation-
interactions (35, 36) have
been shown to be important in other ligand-binding sites such as the
acetylcholine receptor (37).
OH, we determined the effect of chloroquine on
Y652T and Y652E HERG channels. Both mutations reduced the potency and
reversed the voltage dependence of block by chloroquine similar to
Y652A HERG. Thus, the voltage-dependent block of WT HERG
cannot be explained by H-bonding of the drug with a
OH or
COOH
group of non-aromatic amino acids. A possible explanation for the
critical role of Tyr-652, but not simply an
OH group in
voltage-dependent block of HERG, might be the cation-
interaction discussed above for Phe-656. Cation-
interactions are
stronger for Tyr than Phe residues (35), perhaps because the phenolic
OH assists in positioning the face of the aromatic ring in a
preferred orientation for interaction with the cation (N2
or N3 of chloroquine).
80 mV. Low potency could result from an initial
docking involving a cation-
interaction, followed by
-stacking of
the quinoline of chloroquine between Phe-656 residues from multiple
subunits as depicted in docking 1 (Fig. 8B). The
requirement for initial drug docking with Phe-656 could explain why the
voltage dependence for the onset of channel block was nearly the same
(~17 mV/e-fold change in
) regardless if the
fractional block was a positive (WT), negative (Y652A, Y652E, Y652T), or independent (Y652F) function of transmembrane voltage. If
docking to Phe-656 was prevented, for example by mutation of the
residue to Ala, then channel block would be expected to be drastically
reduced, as was observed (Fig. 4F). Increased block of WT
HERG in response to greater membrane depolarization could be explained
by an enhanced occupancy of drug with a distinct higher affinity site.
Based on our experimental findings with Tyr-652 mutant HERG channels,
we propose that interaction with Tyr-652 mediates higher affinity
binding, perhaps as shown for docking 2 depicted in Fig. 8D.
Although not explicitly predicted by this docking, our experimental
findings further suggest that N3 may bind with Tyr-652 by a
cation-
interaction. Decreased interaction of the drug molecule with
multiple Phe-656 residues (docking 1) and enhanced interaction with
Tyr-652 residues could be facilitated by an electrostatic effect on the
positively charged drug as the membrane potential is progressively
depolarized. Mutation of Tyr-652 to Ala would be expected to eliminate
the higher affinity site, but depolarization might still provide an
electrostatic effect that could cause movement of the charged drug
further into the central cavity, away from the Phe-656 residues.
Consistent with this interpretation, complete relief of Y652A and Y652T
HERG channel block was observed in response to strong membrane
depolarization (Figs. 5F and 6F).
OH group, the interaction between
drug and Phe-652 might be similar to the interaction that stabilizes
binding of drug to Phe-656. Two sites with similar binding affinities
could account for the lack of voltage-dependent block.
1c
Ca2+ channels by binding to several S6 residues that face
the central cavity (40). Dihydropyridine agonists interact with some of the same residues, yet cause an increase in Ca2+ channel
conductance (41).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Bert Chenard for helpful discussions, Peter Westenskow for technical assistance, and Olivia Mercado for preparing the figures.
| |
FOOTNOTES |
|---|
* This work was supported by a Fogarty International Research Collaboration Grant R03TW001211, NHLBI Grant R01HL55236 from the National Institutes of Health, and CONACyT (Mexico) Grant 34954-M.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Eccles Institute of
Human Genetics, University of Utah, 15 N 2030 E, Rm. 4220, Salt Lake
City, UT 84112. Tel.: 801-585-6336; Fax: 801-5853501; E-mail:
michael.sanguinetti@hmbg.utah.edu.
Published, JBC Papers in Press, April 17, 2002, DOI 10.1074/jbc.M200448200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HERG, human ether-a-go-go related gene; I-V, current-voltage; WT, wild type; Mes, 4-morpholineethanesulfonic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Warmke, J. W.,
and Ganetzky, B.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3438-3442 |
| 2. | Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995) Cell 81, 299-307[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Trudeau, M.,
Warmke, J. W.,
Ganetzky, B.,
and Robertson, G. A.
(1995)
Science
269,
92-95 |
| 4. | Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995) Cell 80, 795-803[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
El-Sherif, N.,
Caref, E. B.,
Yin, H.,
and Restivo, M.
(1996)
Circ. Res.
79,
474-492 |
| 6. | Roden, D. M. (1998) Am. J. Cardiol. 82, 49I-57I[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Sanghvi, L.,
and Mathur, B. B.
(1965)
Circulation
32,
281-289 |
| 8. | Bustos, M., Gay, F., Diquet, B., Thomare, P., and Warot, D. (1994) Trop. Med. Parasitol. 45, 83-86[Medline] [Order article via Infotrieve] |
| 9. | Harris, L., Downar, E., Shaikh, N. A., and Chen, T. (1988) Can. J. Cardiol. 4, 295-300[Medline] [Order article via Infotrieve] |
| 10. | Fauchier, J., Fauchier, L., Babuty, D., Cosnay, P., and Rouesnel, P. (1993) Arch. Mal. Coeur Vaiss 86 Suppl. 5, 757-767[Medline] [Order article via Infotrieve] |
| 11. |
Sanchez-Chapula, J. A.,
Salinas-Stefanon, E.,
Torres-Jacome, J.,
Benavides-Haro, D. E.,
and Navarro-Polanco, R. A.
(2001)
J. Pharmacol. Exp. Ther.
297,
437-445 |
| 12. |
Mitcheson, J. S.,
Chen, J.,
Lin, M.,
Culberson, C.,
and Sanguinetti, M. C.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12329-12333 |
| 13. |
Lees-Miller, J. P.,
Duan, Y.,
Teng, G. Q.,
and Duff, H. J.
(2000)
Mol. Pharmacol.
57,
367-374 |
| 14. | Hondeghem, L. M., and Katzung, B. G. (1984) Annu. Rev. Pharmacol. Toxicol. 24, 387-423[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Armstrong, C. M.
(1966)
J. Gen. Physiol.
50,
491-503 |
| 16. | Starmer, C. F., and Hollett, M. D. (1985) J. Theor. Biol. 115, 337-349[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Starmer, C. F.
(1987)
Biophys. J.
52,
405-412 |
| 18. | Sarkar, G., and Sommer, S. S. (1990) BioTechniques 8, 404-407[Medline] [Order article via Infotrieve] |
| 19. |
Sanguinetti, M. C.,
and Xu, Q. P.
(1999)
J. Physiol. (Lond.)
514,
667-675 |
| 20. | Stuhmer, W. (1992) Methods Enzymol. 207, 319-339[Medline] [Order article via Infotrieve] |
| 21. |
Doyle, D. A.,
Morais Cabral, J.,
Pfuetzner, R. A.,
Kuo, A.,
Gulbis, J. M.,
Cohen, S. L.,
Chait, B. T.,
and MacKinnon, R.
(1998)
Science
280,
69-77 |
| 22. | Miller, M. D., Kearsley, S. K., Underwood, D. J., and Sheridan, R. P. (1994) J. Comput.-Aided Mol. Des. 8, 153-174 |
| 23. | Yeh, J. Z., and Armstrong, C. M. (1978) Nature 273, 387-389[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Smith, P. L., Baukrowitz, T., and Yellen, G. (1996) Nature 379, 833-836[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Armstrong, C. M.
(1971)
J. Gen. Physiol.
58,
413-437 |
| 26. |
Furukawa, T.,
Tsujimura, Y.,
Kitamura, K.,
Tanaka, H.,
and Habuchi, Y.
(1989)
J. Pharmacol. Exp. Ther.
251,
756-763 |
| 27. |
Balser, J. R.,
Bennett, P. B.,
Hondeghem, L. M.,
and Roden, D. M.
(1991)
Circ. Res.
69,
519-529 |
| 28. |
Kang, J.,
Chen, X. L.,
Wang, L.,
and Rampe, D.
(2001)
J. Pharmacol. Exp. Ther.
299,
290-296 |
| 29. |
Kang, J.,
Wang, L.,
Chen, X. L.,
Triggle, D. J.,
and Rampe, D.
(2001)
Mol. Pharmacol.
59,
122-126 |
| 30. |
Katayama, Y.,
Fujita, A.,
Ohe, T.,
Findlay, I.,
and Kurachi, Y.
(2000)
J. Pharmacol. Exp. Ther.
294,
339-346 |
| 31. |
Kamiya, K.,
Mitcheson, J. S.,
Yasui, K.,
Kodama, I.,
and Sanguinetti, M. C.
(2001)
Mol. Pharmacol.
60,
244-253 |
| 32. | Snyders, D. J., and Chaudhary, A. (1996) Mol. Pharmacol. 49, 949-955[Abstract] |
| 33. |
Spector, P. S.,
Curran, M. E.,
Keating, M. T.,
and Sanguinetti, M. C.
(1996)
Circ. Res.
78,
499-503 |
| 34. |
Carmeliet, E.
(1992)
J. Pharmacol. Exp. Ther.
262,
809-817 |
| 35. | Dougherty, D. A. (1996) Science 271, 163-168[Abstract] |
| 36. |
Mecozzi, S.,
West, A. P., Jr.,
and Dougherty, D. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10566-10571 |
| 37. |
Zhong, W.,
Gallivan, J. P.,
Zhang, Y., Li, L.,
Lester, H. A.,
and Dougherty, D. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12088-12093 |
| 38. |
Roux, B.,
and MacKinnon, R.
(1999)
Science
285,
100-102 |
| 39. | Zhou, M., Morais-Cabral, J. H., Mann, S., and MacKinnon, R. (2001) Nature 411, 657-661[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Peterson, B. Z.,
Johnson, B. D.,
Hockerman, G. H.,
Acheson, M.,
Scheuer, T.,
and Catterall, W. A.
(1997)
J. Biol. Chem.
272,
18752-18758 |
| 41. |
Hockerman, G. H.,
Peterson, B. Z.,
Sharp, E.,
Tanada, T. N.,
Scheuer, T.,
and Catterall, W. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14906-14911 |
This article has been cited by other articles:
![]() |
T. Myokai, S. Ryu, H. Shimizu, and S. Oiki Topological Mapping of the Asymmetric Drug Binding to the Human Ether-a-go-go-Related Gene Product (HERG) Potassium Channel by Use of Tandem Dimers Mol. Pharmacol., June 1, 2008; 73(6): 1643 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Rodriguez-Menchaca, R. A. Navarro-Polanco, T. Ferrer-Villada, J. Rupp, F. B. Sachse, M. Tristani-Firouzi, and J. A. Sanchez-Chapula The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel PNAS, January 29, 2008; 105(4): 1364 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kamiya, R. Niwa, J. S. Mitcheson, and M. C. Sanguinetti Molecular Determinants of hERG Channel Block Mol. Pharmacol., May 1, 2006; 69(5): 1709 - 1716. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Casis, S.-P. Olesen, and M. C. Sanguinetti Mechanism of Action of a Novel Human ether-a-go-go-Related Gene Channel Activator Mol. Pharmacol., February 1, 2006; 69(2): 658 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Perry, P. J. Stansfeld, J. Leaney, C. Wood, M. J. de Groot, D. Leishman, M. J. Sutcliffe, and J. S. Mitcheson Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs Mol. Pharmacol., February 1, 2006; 69(2): 509 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
|